An important component of the cell membrane

 Clinical application

 1, for atherosclerosis, liver failure, abnormal fat metabolism, lipid metabolism blocked the liver (hepatitis, fatty liver) hypercholesterolemia (diabetes, the source of fat-type) arteriosclerosis (brain, the highest artery , Peripheral artery), and other treatment.

 2, apply to hepatitis, gallstones, angina, damage to brain cells, senile dementia, plant nerve disorder (anxiety, irritable, insomnia, tinnitus), the visually-impaired, mentally handicapped and added in the amniotic fluid of pregnant women in the phosphatidylcholine , Is the fetal, infant development of a necessity.

 Pharmaco-toxicological

 The body of the goods involved in lipid metabolism, lower cholesterol, excited cholinergic neurons. Phosphatidylcholine is the synthesis of LDL lipoprotein is the raw material in the form of fat operations, will enable transported to the liver fatty liver, the body involved in the metabolism of fat, fatty liver of a role. Phosphatidylcholine can lower serum cholesterol, triglycerides, elevated high-density lipoprotein, LDL reduction of atherosclerosis prevention and treatment work. At the same time phosphatidylcholine as the premise of acetylcholine, the brain can increase the formation of acetylcholine, excited cholinergic neurons, the brain cells back to work.

 Pharmacokinetics

 The drug oral bioavailability of 90 percent, six hours after the blood concentration reached the peak. The main stomach and intestinal absorption, and metabolism after kidney from, most excluded from the faeces.

 Selected clinical data

 The Third Military Medical University Xinqiao Hospital clinical verification:

 1 egg yolk lecithin-merger Consumers angina treatment of coronary artery disease Colic 2 egg yolk lecithin in the treatment of hyperlipidemia Clinical Efficacy of treatment and clinical effect observed

    Treatment was given egg yolk lecithin tablets (0.1 dose / films) in the treatment group were given single-Central lecithin tablets (0.1 dose / Elements)

 0.3g, and isosorbide dinitrate 10 mg, on the 1st three times a control group given 0.3 g, on the 1st three times a control group given nicotinic acid inositol lipid

 Isosorbide dinitrate 10 mg, on the 1st three times, the course of two months. Treatment of 0.3g, on the 1st three times, the course of two months. The treatment of the results are as follows: fruit the following